{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:52:10Z","timestamp":1789480330438,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gastric cancer (GC) is a highly prevalent type of malignant tumor worldwide. Patients with locally advanced gastric cancer (LAGC) frequently have a poor prognosis due to the inability to achieve R0 resection. Neoadjuvant chemotherapy (NAC) can enhance survival rates, although its effectiveness is limited. Immune checkpoint inhibitors (ICIs) have demonstrated potential in treating advanced gastric cancer, but their efficacy in neoadjuvant therapy (NAT) for LAGC remains unclear. The aim of this study was to evaluate the safety, pathological response and survival outcome of neoadjuvant chemotherapy plus immunotherapy (NACI) versus NAC alone after laparoscopic gastrectomy for GC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of 375 patients with LAGC who received neoadjuvant therapy from 2015 to 2022 was performed. Patients were divided into NACI group (168 patients) and NAC group (207 patients) according to NAT regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The rate of pathologic complete response (pCR, 20.2% vs. 12.6%, P=0.04) and the rate of major pathological response (MPR, 31.0% vs. 18.8%, P=0.007) in the NACI group are significantly higher than those in the NAC group, and the NACI group also had a higher rate of R0 resection (91.3% vs. 84.1%, P=0.028). The NACI group experienced a more significant decline in ypT0 (22.0% vs. 13.0%, P=0.022) and ypN0 (67.3% vs. 53.6%, P=007), but there was no difference in disease-free survival (DFS) and overall survival (OS) at 3 years between the two groups (P&amp;gt;0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>NACI significantly improved pCR rates and R0 resection rates in patients with LAGC without increasing perioperative risk, but did not translate into short-term survival benefits.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1672547","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:34:51Z","timestamp":1756964091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of laparoscopic radical gastrectomy after neoadjuvant chemotherapy plus immunotherapy: a retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Junjie","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0231","article-title":"Current cancer burden in China: epidemiology, etiology, and prevention","volume":"19","author":"Maomao","year":"2022","journal-title":"Cancer Biol Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.21147\/j.issn.1000-9604.2023.02.01","article-title":"Stomach cancer burden in China: epidemiology and prevention","volume":"35","author":"Yan","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an fnclcc and ffcd multicenter phase iii trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (Flot4): A randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, nccn clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The chinese society of clinical oncology (Csco): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the pd1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (Checkmate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with her2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (Attraction-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0182","article-title":"Surgical management of gastric cancer: A review","volume":"157","author":"Li","year":"2022","journal-title":"JAMA Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v13.i12.2161","article-title":"Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy","volume":"13","author":"Liu","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783243","article-title":"Safety and efficacy of camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijsu.2018.10.044","article-title":"Relationship between clavien-dindo classification and long-term survival outcomes after curative resection for gastric cancer: A propensity score-matched analysis","volume":"60","author":"Li","year":"2018","journal-title":"Int J Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: A multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1078196","article-title":"Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study","volume":"13","author":"Su","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001468","article-title":"The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: A multicentre real-world clinical study","volume":"110","author":"Sun","year":"2024","journal-title":"Int J Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-pd-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122121","article-title":"Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13578-025-01424-8","article-title":"Alpha fetoprotein (Afp)-producing gastric cancer: clinicopathological features and treatment strategies","volume":"15","author":"Luo","year":"2025","journal-title":"Cell Biosci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01258-6","article-title":"Prognostic value of tumor markers and ctdna in patients with resectable gastric cancer receiving perioperative treatment: results from the critics trial","volume":"25","author":"Slagter","year":"2022","journal-title":"Gastric Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05131-0","article-title":"Prognostic significance of post-preoperative tumor markers increments in patients with non-metastatic gastric cancer","volume":"149","author":"Zhu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1525324","article-title":"Carcinoembryonic antigen trajectory predicts pathological complete response in advanced gastric cancer after neoadjuvant chemotherapy","volume":"15","author":"Chen","year":"2025","journal-title":"Front Oncol"},{"key":"B35","year":""},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.927781","article-title":"Efficacy and safety of sintilimab plus xelox as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase ii trial","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study","volume":"10","author":"Jiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10120-016-0615-3","article-title":"The italian research group for gastric cancer (Gircg) guidelines for gastric cancer staging and treatment: 2015","volume":"20","author":"De Manzoni","year":"2017","journal-title":"Gastric Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","article-title":"The efficacy and safety of pd-1\/pd-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, her2-negative gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials","volume":"16","author":"Pu","year":"2025","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr291","article-title":"Phase ii trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-fu in locally advanced esophageal and gastric cancer","volume":"23","author":"Pera","year":"2012","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of pd-1\/pd-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2135819","article-title":"Neoadjuvant pd-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage iii gastric cancer","volume":"11","author":"Tang","year":"2022","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00262-024-03802-6","article-title":"The short-term efficacy of neoadjuvant sox versus sox plus immune checkpoint inhibitor following laparoscopic gastrectomy for locally advanced gastric cancer: A multicenter retrospective cohort study in China","volume":"73","author":"Cui","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6471-0","article-title":"Nodal downstaging in gastric cancer patients: promising survival if ypn0 is achieved","volume":"25","author":"Ikoma","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (Keynote-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1322152","article-title":"Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0165179","DOI":"10.1371\/journal.pone.0165179","article-title":"Does total gastrectomy provide better outcomes than distal subtotal gastrectomy for distal gastric cancer? A systematic review and meta-analysis","volume":"11","author":"Qi","year":"2016","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.20141566","article-title":"Proximal gastric cancer: lymph node metastatic patterns according to different T stages dictate surgical approach","volume":"127","author":"Song","year":"2014","journal-title":"Chin (Engl)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S157378","article-title":"Clinicopathologic characteristics and prognosis of proximal and distal gastric cancer","volume":"11","author":"Yu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i4.1281","article-title":"Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with borrmann large type iii and iv gastric cancers","volume":"16","author":"Bao","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:34:53Z","timestamp":1756964093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2025.1672547"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1672547","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1672547"}}